Retrospective study of alectinib on long-term prognosis in poor performance status patients with ALK positive, advanced/recurrent NSCLC
Latest Information Update: 13 Jul 2021
At a glance
- Drugs Alectinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LOGIK1401-B
Most Recent Events
- 18 Feb 2019 New trial record